Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Galecto, Inc. stock logo
GLTO
Galecto
$3.53
+1.6%
$3.18
$2.01
$16.07
$4.65M1.3585,226 shs48,712 shs
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
$0.03
+1.5%
$0.03
$0.02
$0.14
$2.04M1.8994,160 shs9,946 shs
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
$3.38
-2.9%
$2.55
$1.61
$11.20
$216.42M0.86841,332 shs686,310 shs
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$2.14
+0.9%
$2.19
$1.82
$3.09
$87.42M1.59141,110 shs18,716 shs
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
$0.31
$0.30
$0.22
$1.14
$53.51M0.931.01 million shs2.68 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Galecto, Inc. stock logo
GLTO
Galecto
+2.50%+1.01%+3.72%+50.22%-72.18%
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
-6.34%-9.52%+12.24%+10.37%-80.86%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
+0.58%+10.83%+19.59%+92.27%-61.99%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-2.30%-2.93%-4.93%+0.47%-14.86%
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Galecto, Inc. stock logo
GLTO
Galecto
3.2685 of 5 stars
3.55.00.00.00.71.71.3
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
0.309 of 5 stars
0.03.00.00.00.61.70.0
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
1.5577 of 5 stars
3.61.00.00.01.11.70.0
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
0.2984 of 5 stars
0.03.00.00.00.00.80.6
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Galecto, Inc. stock logo
GLTO
Galecto
3.00
Buy$10.00182.49% Upside
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
0.00
N/AN/AN/A
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3.11
Buy$18.50441.57% Upside
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
2.00
HoldN/AN/A
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ORMP, GRTX, LRMR, GLTO, and TYME Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
6/24/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$17.00 ➝ $15.00
6/24/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$26.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Galecto, Inc. stock logo
GLTO
Galecto
N/AN/AN/AN/A$10.99 per shareN/A
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/A($2.41) per shareN/A
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/AN/AN/AN/A$2.69 per shareN/A
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$1.34M65.54N/AN/A$3.61 per share0.60
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
N/AN/AN/AN/A$0.47 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Galecto, Inc. stock logo
GLTO
Galecto
-$21.44M-$15.53N/AN/AN/AN/A-98.27%-84.29%8/11/2025 (Estimated)
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
-$59.08M-$0.26N/AN/AN/AN/A-99.34%8/12/2025 (Estimated)
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$80.60M-$1.49N/AN/AN/AN/A-52.48%-46.08%8/6/2025 (Estimated)
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-$19.06M-$0.44N/AN/AN/AN/A-11.34%-10.73%8/13/2025 (Estimated)
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
-$23.63M-$0.14N/AN/AN/A-28.30%-26.21%N/A

Latest ORMP, GRTX, LRMR, GLTO, and TYME Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$0.4877N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-$0.03-$0.19-$0.16-$0.19N/A$2.00 million
5/8/2025Q1 2025
Galecto, Inc. stock logo
GLTO
Galecto
N/A-$1.92N/A-$1.92N/AN/A
4/30/2025Q1 2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$0.42-$0.46-$0.04-$0.46N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Galecto, Inc. stock logo
GLTO
Galecto
N/AN/AN/AN/AN/A
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/AN/A
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/AN/AN/AN/AN/A
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
N/AN/AN/AN/AN/A
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Galecto, Inc. stock logo
GLTO
Galecto
N/A
9.62
9.62
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/A
9.74
9.74
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/A
7.48
7.48
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
N/A
23.94
23.94
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
N/A
14.06
14.06

Institutional Ownership

CompanyInstitutional Ownership
Galecto, Inc. stock logo
GLTO
Galecto
14.20%
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
50.77%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
91.92%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
12.73%
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
16.69%

Insider Ownership

CompanyInsider Ownership
Galecto, Inc. stock logo
GLTO
Galecto
10.80%
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
12.90%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
4.50%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
13.70%
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
16.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Galecto, Inc. stock logo
GLTO
Galecto
401.32 million1.18 millionOptionable
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
3075.46 million47.38 millionOptionable
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3064.03 million61.15 millionOptionable
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
1040.85 million35.25 millionOptionable
Tyme Technologies, Inc. stock logo
TYME
Tyme Technologies
17172.21 million143.10 millionOptionable

Recent News About These Companies

How Nubank’s Investment in Tyme Helps African Startups
TymeBank parent valued at $1.5-billion in latest fundraise
Brazilian fintech giant invests in SA-born Tyme Group
Multi-billion funding bolsters Tyme Group valuation
Best Restaurants in Leominster, Massachusetts
Best Restaurants in Quincy, Illinois
Best Restaurants in Peoria, Illinois

New MarketBeat Followers Over Time

Media Sentiment Over Time

Galecto stock logo

Galecto NASDAQ:GLTO

$3.53 +0.06 (+1.61%)
Closing price 03:55 PM Eastern
Extended Trading
$3.52 0.00 (-0.03%)
As of 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Galera Therapeutics stock logo

Galera Therapeutics NASDAQ:GRTX

$0.03 +0.00 (+1.50%)
As of 02:43 PM Eastern

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

Larimar Therapeutics stock logo

Larimar Therapeutics NASDAQ:LRMR

$3.38 -0.10 (-2.87%)
Closing price 04:00 PM Eastern
Extended Trading
$3.38 0.00 (0.00%)
As of 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Oramed Pharmaceuticals stock logo

Oramed Pharmaceuticals NASDAQ:ORMP

$2.14 +0.02 (+0.94%)
Closing price 04:00 PM Eastern
Extended Trading
$2.13 -0.01 (-0.23%)
As of 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Tyme Technologies stock logo

Tyme Technologies NASDAQ:TYME

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.